Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China

Table 1 Univariate analysis of pretreatment variables

Variable	Patients	Survival time (%)			Median survival length (mo)	P value
	n (%)	1 yr	5 yr	10 yr
Age (yr)
≤ 50	848 (54.0)	46	9	7	9.63	0.003
> 50	721 (46.0)	49	11	7	11.60	-
HBV
HBsAg(-)HBeAg(-)	215 (13.8)	55	15	12	13.70	0.000
HBsAg(+)HBeAg(-)	811 (52.2)	50	11	9	11.43	-
HBsAg(+)HBeAg(+)	529 (34.0)	40	7	3	8.27	-
AFP (ng/mL)
≤ 20	292 (19.0)	61	18	-	15.80	0.000
21-200	296 (19.3)	56	13	9	13.50	-
> 200	946 (61.7)	41	7	6	8.53	-
Child-Pugh grade
A	1413 (90.8)	49	11	8	10.97	0.000
B	144 (9.2)	34	6	4	6.40	-
Nodules
≤ 3	855 (54.5)	52	12	8	12.30	0.000
> 3	714 (45.5)	42	8	-	8.57	-
Greatest dimension (cm)
≤ 5.0	164 (10.5)	71	25	16	19.03	0.000
5.1-10	624 (39.8)	50	11	6	11.77	-
10.1-15	606 (38.6)	43	8	7	9.10	-
> 15	175 (11.2)	29	3	-	6.10	-
Tumor capsule
No	818 (52.8)	41	9	5	8.40	0.000
Yes	732 (47.2)	55	11	9	12.50	-
Macrovascular invasion
No	1276 (81.3)	50	12	8	11.70	0.000
Yes	293 (18.7)	34	3	-	7.10	-
Regional lymph node metastasis
No	1519 (96.8)	48	10	7	10.50	0.032
Yes	50 (3.2)	31	8	-	7.10	-
Distant metastasis
No	1302 (82.9)	48	12	8	10.40	0.183
Yes	269 (17.1)	46	4	-	10.13	-

Table 2 Relative risk of survival for significant pretreatment variables

Variable	P value	Hazard ratio (95% CI)
Regional lymph nodes metastasis	0.001	1.736 (1.272-2.370)
Child-Pugh class	0.017	1.254 (1.041-1.510)
Macrovascular invasion	0.002	1.253 (1.083-1.450)
Greatest dimension	0.000	1.250 (1.167-1.340)
AFP	0.000	1.237 (1.149-1.333)
HBV	0.000	1.232 (1.130-1.343)
Tumor capsule	0.004	1.192 (1.059-1.343)
Nodules	0.012	1.164 (1.034-1.310)

AFP: α-fetoprotein; HBV: Hepatitis B virus.